About Dynein axonemal heavy chain 2
Dynein axonemal heavy chain 2 (DNAH2) is a protein
from Homo sapiens identified by UniProt accession
Q9P225, 4427 residues long.
MolForge cross-references it against 0 known binders and
173 disease associations.
Target properties
| Protein name | Dynein axonemal heavy chain 2 |
|---|
| UniProt accession | Q9P225 |
|---|
| Gene | DNAH2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 4427 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (173)
Diseases linked to this target (Open Targets).
- spermatogenic failure 45 · score 0.61
- genetic disorder · score 0.19
- hemoglobin measurement · score 0.17
- Primary microcephaly · score 0.17
- sex hormone-binding globulin measurement · score 0.16
- platelet count · score 0.15
- erythrocyte count · score 0.14
- hematocrit · score 0.14
- mean corpuscular volume · score 0.13
- platelet crit · score 0.12
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (4427 residues)
MSSKAEKKQR LSGRGSSQAS WSGRATRAAV ATQEQGNAPA VSEPELQAEL PKEEPEPRLE GPQAQSEESV EPEADVKPLF LSRAALTGLA DAVWTQEHDA ILEHFAQDPT ESILTIFIDP CFGLKLELGM PVQTQNQLVY FIRQAPVPIT WENFEATVQF GTVRGPYIPA LLRLLGGVFA PQIFANTGWP ESIRNHFASH LHKFLACLTD TRYKLEGHTV LYIPAEAMNM KPEMVIKDKE LVQRLETSMI HWTRQIKEML SAQETVETGE NLGPLEEIEF WRNRCMDLSG ISKQLVKKGV KHVESILHLA KSSYLAPFMK LAQQIQDGSR QAQSNLTFLS ILKEPYQELA FMKPKDISSK LPKLISLIRI IWVNSPHYNT RERLTSLFRK VCDCQYHFAR WEDGKQGPLP CFFGAQGPQI TRNLLEIEDI FHKNLHTLRA VRGGILDVKN TCWHEDYNKF RAGIKDLEVM TQNLITSAFE LVRDVPHGVL LLDTFHRLAS REAIKRTYDK KAVDLYMLFN SELALVNRER NKKWPDLEPY VAQYSGKARW VHILRRRIDR VMTCLAGAHF LPRIGTGKES VHTYQQMVQA IDELVRKTFQ EWTSSLDKDC IRRLDTPLLR ISQEKAGMLD VNFDKSLLIL FAEIDYWERL LFETPHYVVN VAERAEDLRI LRENLLLVAR DYNRIIAMLS PDEQALFKER IRLLDKKIHP GLKKLHWALK GASAFFITEC RIHASKVQMI VNEFKASTLT IGWRAQEMSE KLLVRISGKR VYRDLEFEED QREHRAAVQQ KLMNLHQDVV TIMTNSYEVF KNDGPEIQQQ WMLYMIRLDR MMEDALRLNV KWSLLELSKA INGDGKTSPN PLFQVLVILK NDLQGSVAQV EFSPTLQTLA GVVNDIGNHL FSTISVFCHL PDILTKRKLH REPIQTVVEQ DEDIKKIQTQ ISSGMTNNAS LLQNYLKTWD MYREIWEINK DSFIHRYQRL NPPVSSFVAD IARYTEVANN VQKEETVTNI QFVLLDCSHL KFSLVQHCNE WQNKFATLLR EMAAGRLLEL HTYLKENAEK ISRPPQTLEE LGVSLQLVDA LKHDLANVET QIPPIHEQFA ILEKYEVPVE DSVLEMLDSL NGEWVVFQQT LLDSKQMLKK HKEKFKTGLI HSADDFKKKA HTLLEDFEFK GHFTSNVGYM SALDQITQVR AMLMAMREEE NSLRANLGIF KIEQPPSKDL QNLEKELDAL QQIWEIARDW EENWNEWKTG RFLILQTETM ETTAHGLFRR LTKLAKEYKD RNWEIIETTR SKIEQFKRTM PLISDLRNPA LRERHWDQVR DEIQREFDQE SESFTLEQIV ELGMDQHVEK IGEISASATK ELAIEVALQN IAKTWDVTQL DIVPYKDKGH HRLRGTEEVF QALEDNQVAL STMKASRFVK AFEKDVDHWE RCLSLILEVI EMILTVQRQW MYLENIFLGE DIRKQLPNES TLFDQVNSNW KAIMDRMNKD NNALRSTHHP GLLDTLIEMN TILEDIQKSL DMYLETKRHI FPRFYFLSND DLLEILGQSR NPEAVQPHLK KCFDNIKLLR IQKVGGPSSK WEAVGMFSGD GEYIDFLHSV FLEGPVESWL GDVEQTMRVT LRDLLRNCHL ALRKFLNKRD KWVKEWAGQV VITASQIQWT ADVTKCLLTA KERADKKILK VMKKNQVSIL NKYSEAIRGN LTKIMRLKIV ALVTIEIHAR DVLEKLYKSG LMDVNSFDWL SQLRFYWEKD LDDCVIRQTN TQFQYNYEYL GNSGRLVITP LTDRCYMTLT TALHLHRGGS PKGPAGTGKT ETVKDLGKAL GIYVIVVNCS EGLDYKSMGR MYSGLAQTGA WGCFDEFNRI NIEVLSVVAH QILCILSALA AGLTHFHFDG FEINLVWSCG IFITMNPGYA GRTELPENLK SMFRPIAMVV PDSTLIAEII LFGEGFGNCK ILAKKVYTLY SLAVQQLSRQ DHYDFGLRAL TSLLRYAGKK RRLQPDLTDE EVLLLSMRDM NIAKLTSVDA PLFNAIVQDL FPNIELPVID YGKLRETVEQ EIRDMGLQST PFTLTKVFQL YETKNSRHST MIVGCTGSGK TASWRILQAS LSSLCRAGDP NFNIVREFPL NPKALSLGEL YGEYDLSTNE WTDGILSSVM RTACADEKPD EKWILFDGPV DTLWIENMNS VMDDNKVLTL INGERIAMPE QVSLLFEVED LAMASPATVS RCGMVYTDYA DLGWKPYVQS WLEKRPKAEV EPLQRMFEKL INKMLAFKKD NCKELVPLPE YSGITSLCKL YSALATPENG VNPADGENYV TMVEMTFVFS MIWSVCASVD EEGRKRIDSY LREIEGSFPN KDTVYEYFVD PKIRSWTSFE DKLPKSWRYP PNAPFYKIMV PTVDTVRYNY LVSSLVANQN PILLVGPVGT GKTSIAQSVL QSLPSSQWSV LVVNMSAQTT SNNVQSIIES RVEKRTKGVY VPFGGKSMIT FMDDLNMPAK DMFGSQPPLE LIRLWIDYGF WYDRTKQTIK YIREMFLMAA MGPPGGGRTV ISPRLRSRFN IINMTFPTKS QIIRIFGTMI NQKLQDFEEE VKPIGNVVTE ATLDMYNTVV QRFLPTPTKM HYLFNLRDIS KVFQGMLRAN KDFHDTKSSI TRLWIHECFR VFSDRLVDAA DTEAFMGIIS DKLGSFFDLT FHHLCPSKRP PIFGDFLKEP KVYEDLTDLT VLKTVMETAL NEYNLSPSVV PMQLVLFREA IEHITRIVRV IGQPRGNMLL VGIGGSGRQS LARLASSICD YTTFQIEVTK HYRKQEFRDD IKRLYRQAGV ELKTTSFIFV DTQIADESFL EDINNILSSG EVPNLYKPDE FEEIQSHIID QARVEQVPES SDSLFAYLIE RVQNNLHIVL CLSPMGDPFR NWIRQYPALV NCTTINWFSE WPQEALLEVA EKCLIGVDLG TQENIHRKVA QIFVTMHWSV AQYSQKMLLE LRRHNYVTPT KYLELLSGYK KLLGEKRQEL LAQANKLRTG LFKIDETREK VQVMSLELED AKKKVAEFQK QCEEYLVIIV QQKREADEQQ KAVTANSEKI AVEEIKCQAL ADNAQKDLEE ALPALEEAMR ALESLNKKDI GEIKSYGRPP AQVEIVMQAV MILRGNEPTW AEAKRQLGEQ NFIKSLINFD KDNISDKVLK KIGAYCAQPD FQPDIIGRVS LAAKSLCMWV RAMELYGRLY RVVEPKRIRM NAALAQLREK QAALAEAQEK LREVAEKLEM LKKQYDEKLA QKEELRKKSE EMELKLERAG MLVSGLAGEK ARWEETVQGL EEDLGYLVGD CLLAAAFLSY MGPFLTNYRD EIVNQIWIGK IWELQVPCSP SFAIDNFLCN PTKVRDWNIQ GLPSDAFSTE NGIIVTRGNR WALMIDPQAQ ALKWIKNMEG GQGLKIIDLQ MSDYLRILEH AIHFGYPVLL QNVQEYLDPT LNPMLNKSVA RIGGRLLMRI GDKEVEYNTN FRFYITTKLS NPHYSPETSA KTTIVNFAVK EQGLEAQLLG IVVRKERPEL EEQKDSLVIN IAAGKRKLKE LEDEILRLLN EATGSLLDDV QLVNTLHTSK ITATEVTEQL ETSETTEINT DLAREAYRPC AQRASILFFV LNDMGCIDPM YQFSLDAYIS LFILSIDKSH RSNKLEDRID YLNDYHTYAV YRYTCRTLFE RHKLLFSFHM CAKILETSGK LNMDEYNFFL RGGVVLDREG QMDNPCSSWL ADAYWDNITE LDKLTNFHGL MNSFEQYPRD WHLWYTNAAP EKAMLPGEWE NACNEMQRML IVRSLRQDRV AFCVTSFIIT NLGSRFIEPP VLNMKSVLED STPRSPLVFI LSPGVDPTSA LLQLAEHMGM AQRFHALSLG QGQAPIAARL LREGVTQGHW VFLANCHLSL SWMPNLDKLV EQLQVEDPHP SFRLWLSSIP HPDFPISILQ VSIKMTTEPP KGLKANMTRL YQLMSEPQFS RCSKPAKYKK LLFSLCFFHS VLLERKKFLQ LGWNIIYGFN DSDFEVSENL LSLYLDEYEE TPWDALKYLI AGINYGGHVT DDWDRRLLTT YINDYFCDQS LSTPFHRLSA LETYFIPKDG SLASYKEYIS LLPGMDPPEA FGQHPNADVA SQITEAQTLF DTLLSLQPQI TPTRAGGQTR EEKVLELAAD VKQKIPEMID YEGTQKLLAL DPSPLNVVLL QEIQRYNTLM QTILFSLTDL EKGIQGLIVM STSLEEIFNC IFDAHVPPLW GKAYPSQKPL AAWTRDLAMR VEQFELWASR ARPPVIFWLS GFTFPTGFLT AVLQSSARQN NVSVDSLSWE FIVSTVDDSN LVYPPKDGVW VRGLYLEGAG WDRKNSCLVE AEPMQLVCLM PTIHFRPAES RKKSAKGMYS CPCYYYPNRA GSSDRASFVI GIDLRSGAMT PDHWIKRGTA LLMSLDS
Explore Dynein axonemal heavy chain 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets